Bictegravir

BIC is only available as a component of the STR Biktarvy (BIC/TAF/FTC).

ARV U.S. Brand Name

Biktarvy

ARV Abbreviation(s)

BIC

ARV Class

Integrase inhibitors

First U.S. Approval

February 7, 2018

U.S. Manufacturer

Gilead Sciences

Formulations

Strength	Formulation	Image	Description	Boosted
50 mg of bictegravir, 200 mg of emtricitabine , 25 mg of tenofovir alafenamide	Tablet	X	Mauve oblong tablet with "GSI" imprinted	No
	Subcutaneous Injection	X	Islatravir/subdermal drug-eluting implant	No

Generic Available?

FDCs

Bictegravir / Emtricitabine / Tenofovir alafenamide

Assistance Programs

Gilead Advancing Access

Displaying 1 - 24 of 24

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Bictegravir Disopyramide 85	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential increase in disopyramide effects				If coadministering, monitor for disopyramide adverse effects
Bictegravir Dexamethasone 84	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decrease in bictegravir levels and antiretroviral efficacy after chronic administration				If coadministering, monitor for antiretroviral efficacy. If using long-term, consider using alternative corticosteroid or antiretroviral.
Bictegravir Voriconazole 83	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potentially increased bictegravir adverse effects	Cmax increased 9%, AUC increased 61%	300 mg BID (fasted state)	Not reported	Consider using alternative agents; if coadministering, monitor for bictegravir adverse effects
Bictegravir RFB 82	Red: Avoid combination	Do not coadminister: Reduced levels of bictegravir	Potential decrease in antiretroviral efficacy	Cmax decreased 20%, AUC decreased 38%, Cmin decreased 56%	300 mg once daily (fasted)	Not reported	Use alternative agents
Bictegravir RIF 81	Red: Avoid combination	Do not coadminister: Reduced levels of bictegravir	Potential decrease in antiretroviral efficacy	Cmax decreased 28%, AUC decreased 75%	600 mg once daily (fed state)	Not reported	Contraindicated. Use alternative agents.
Bictegravir Phenytoin 80	Red: Avoid combination	Do not coadminister: Potential for reduced levels of BIC and TAF	Potential decrease in antiretroviral efficacy				Use alternative agents
Bictegravir Phenobarbital 79	Red: Avoid combination	Do not coadminister: Potential for reduced levels of BIC and TAF	Potential decrease in antiretroviral efficacy				Use alternative agents
Bictegravir Oxcarbazepine 78	Red: Avoid combination	Do not coadminister: Potential for reduced levels of BIC and TAF	Potential decrease in antiretroviral efficacy				Use alternative agents
Bictegravir CBZ 77	Red: Avoid combination	Do not coadminister: Potential for reduced levels of BIC and TAF	Potential decrease in antiretroviral efficacy				Use alternative agents
Bictegravir St. John's Wort (Hypericum perforatum) 76	Red: Avoid combination	Do not coadminister: Potential for reduced levels of BIC and TAF	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents.
Bictegravir Eslicarbazepine 75	Red: Avoid combination	Do not coadminister: Potential for reduced levels of BIC and TAF	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents.
Bictegravir RPT 74	Red: Avoid combination	Do not coadminister: Potential for reduced levels of BIC	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Use alternative agents
Bictegravir Primidone 73	Red: Avoid combination	Do not coadminister: Potential for reduced levels of BIC	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents.
Bictegravir Enzalutamide 72	Red: Avoid combination	Do not coadminister: Potential for reduced levels of BIC	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents.
Bictegravir Dofetilide 71	Red: Avoid combination	Do not coadminister: Potential for increased levels of dofetilide	Potentially increased dofetilide exposure and cardiac arrhythmias				Contraindicated. Use alternative agents.
Bictegravir SOF/VEL/VOX 70	Green: Administer standard doses	Administer standard doses		Cmax decreased 2%, AUC increased 7%, Cmin increased 10%	400 / 100 / 100 + 100 voxilaprevir once daily (fed state)	Sofosbuvir Cmax increased 14%, AUC increased 9%. Velpatasvir Cmax decreased 4%, AUC decreased 4%, Cmin decreased 6%. Voxilaprevir Cmax decreased 10%, AUC decreased 9%, Cmin decreased 3%
Bictegravir LDV/SOF 69	Green: Administer standard doses	Administer standard doses		Cmax decreased 2%, Cmin increased 4%	90 / 400 mg once daily	Ledipasvir Cmax decreased 15%, AUC decreased 13%. Sofosbuvir Cmax increased 11%, AUC increased 7%
Bictegravir EE/NGM 68	Green: Administer standard doses	Administer standard doses		Not reported	EE 0.025mg once daily with NGM 0.180 / 0.215 / 0.250mg once daily	Ethinyl estradiol Cmax inccreased 15%, AUC increased 4%, Cmin increased 5%. Norelgestromin Cmax increased 23%, AUC increased 8%, Cmin increased 10%. Norgestrel Cmax increase 15%, AUC increase 13%, Cmin increase 14%
Bictegravir Midazolam 67	Green: Administer standard doses	Administer standard doses	Potential for increased sedation	Not reported	2 mg single dose	Cmax increased 3%, AUC increased 15%
Bictegravir Metformin 66	Green: Administer standard doses	Administer standard doses	Potential increase in metformin adverse effects (gastrointestinal)	Not reported	500 mg BID	Cmax inccreased 28%, AUC increased 39%, Cmin increased 36%
Bictegravir Iron 65	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of bictegravir	Potential decrease in antiretroviral efficacy	If administered simultaneously in the fasted state Cmax decreased 71%, AUC decreased 63%. If administered simultaneously in the fed state Cmax decreased 25%, AUC decreased 16%	324 mg single dose	Not reported	Bictegravir should be administered simultaenously with iron supplements, with food. Monitor for virologic efficacy.
Bictegravir Calcium carbonate 64	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of bictegravir	Potential decrease in antiretroviral efficacy	If administered simultaneously in the fasted state Cmax decreased 42%, AUC decreased 33%. If administered simultaneously in the fed state Cmax decreased 10%, AUC increased 3%	1200 mg single dose	Not reported	Bictegravir should be administered simultaenously with calcium carbonate supplements, with food.
Bictegravir Calcium carbonate 63	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of bictegravir	Potential decrease in antiretroviral efficacy	If administered simultaneously in the fasted state Cmax decreased 42%, AUC decreased 33%. If administered simultaneously in the fed state Cmax decreased 10%, AUC increased 3%	1200 mg single dose	Not reported	Bictegravir should be administered simultaenously with calcium carbonate supplements, with food.
Bictegravir

Subscribe to Bictegravir